Glutaredoxin deficiency exacerbates neurodegeneration in C. Elegans models of Parkinson's disease

Human Molecular Genetics

Volumn 24, Issue 5, 2015, Pages 1322-1335

  Johnson, William M ^a   Yao, Chen ^a   Siedlak, Sandra L ^a   Wang, Wenzhang ^a   Zhu, Xiongwei ^a   Caldwell, Guy A ^b   Wilson Delfosse, Amy L ^a   Mieyal, John J ^a,c   Chen, Shu G ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLUTAREDOXIN; GLUTAREDOXIN 1; LEUCINE RICH REPEAT KINASE 2; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; CYSTEINE; HELMINTH PROTEIN; LRRK2 PROTEIN, HUMAN; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE;

ARTICLE; AUTOPSY; BRAIN TISSUE; CAENORHABDITIS ELEGANS; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; HUMAN TISSUE; MESENCEPHALON; NERVE DEGENERATION; NEUROPROTECTION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; ANIMAL; CELL SURVIVAL; DEFICIENCY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR EVOLUTION; OXIDATIVE STRESS; PHENOTYPE;

CAENORHABDITIS ELEGANS;

ALPHA-SYNUCLEIN; ANIMALS; CAENORHABDITIS ELEGANS; CELL SURVIVAL; CYSTEINE; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION; GLUTAREDOXINS; HELMINTH PROTEINS; HOMEOSTASIS; HUMANS; MESENCEPHALON; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; TYROSINE 3-MONOOXYGENASE;

EID: 84924514137     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu542     Document Type: Article

References (45)

1. Bai, J., Nakamura, H., Hattori, I., Tanito,M. and Yodoi, J. (2002) Thioredoxin suppresses 1-methyl-4-phenylpyridiniuminduced neurotoxicity in rat PC12 cells. Neurosci. Lett., 321, 81-84.
2. Hu, X.,Weng, Z., Chu, C.T., Zhang, L., Cao, G., Gao, Y., Signore, A., Zhu, J., Hastings, T., Greenamyre, J.T. et al. (2011) Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J. Neurosci., 31, 247-261.
3. De Simoni, S., Goemaere, J. and Knoops, B. (2008) Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+. Neurosci. Lett., 433, 219-224.
4. Sabens, E.A., Distler, A.M. and Mieyal, J.J. (2010) Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: implications for therapy of Parkinson's disease. Biochemistry, 49, 2715-2724.
5. Johnson, W.M., Wilson-Delfosse, A.L. and Mieyal, J.J. (2012) Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients, 4, 1399-1440.
6. Filloux, F. and Townsend, J.J. (1993) Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol., 119, 79-88.
7. Gomez-Santos, C., Ferrer, I., Santidrian, A.F., Barrachina, M., Gil, J. and Ambrosio, S. (2003) Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells. J. Neurosci. Res., 73, 341-350.
8. Ham, A., Kim, D.W., Kim, K.H., Lee, S.J., Oh, K.B., Shin, J. and Mar, W. (2013) Reynosin protects against neuronal toxicity in dopamine-induced SH-SY5Y cells and 6-hydroxydopamine- lesioned rats as models of Parkinson's disease: reciprocal up-regulation of E6-AP and down-regulation of alpha-synuclein. Brain Res., 1524, 54-61.
9. Singleton, A.B., Farrer, M.J. and Bonifati, V. (2013) The genetics of Parkinson's disease: progress and therapeutic implications. Mov. Disord., 28, 14-23.
10. Gandhi, P.N., Chen, S.G. andWilson-Delfosse, A.L. (2009) Leucine- rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J. Neurosci. Res., 87, 1283-1295.
11. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
12. Wang, X., Yan, M.H., Fujioka, H., Liu, J., Wilson-Delfosse, A., Chen, S.G., Perry, G., Casadesus, G. and Zhu, X. (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. Genet., 21, 1931-1944.
13. Dryanovski, D.I., Guzman, J.N., Xie, Z., Galteri, D.J., Volpicelli-Daley, L.A., Lee, V.M., Miller, R.J., Schumacker, P.T. and Surmeier, D.J. (2013) Calcium entry and alpha-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J. Neurosci., 33, 10154-10164.
14. Gallogly, M.M., Starke, D.W., Leonberg, A.K., Ospina, S.M. and Mieyal, J.J. (2008) Kinetic and mechanistic characterization and versatile catalytic properties of mammalian glutaredoxin 2: implications for intracellular roles. Biochemistry, 47, 11144-11157.
15. Mieyal, J.J., Gallogly, M.M., Qanungo, S., Sabens, E.A. and Shelton, M.D. (2008) Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid. Redox Signal., 10, 1941-1988.
16. Shelton, M.D., Chock, P.B. and Mieyal, J.J. (2005) Glutaredoxin: role in reversible protein S-glutathionylation and regulation of redox signal transduction and protein translocation. Antioxid. Redox Signal., 7, 348-366.
17. Rodriguez-Rocha, H., Garcia Garcia, A., Zavala-Flores, L., Li, S., Madayiputhiya, N. and Franco, R. (2012) Glutaredoxin 1 protects dopaminergic cells by increased protein glutathionylation in experimental Parkinson's disease. Antioxid. Redox Signal., 17, 1676-1693.
18. Kenchappa, R.S. and Ravindranath, V. (2003) Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP. FASEB J., 17, 717-719.
19. Kenchappa, R.S., Diwakar, L., Annepu, J. and Ravindranath, V. (2004) Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration. FASEB J., 18, 1102-1104.
20. Daigle, I. and Li, C. (1993) apl-1, a Caenorhabditis elegans gene encoding a protein related to the human beta-amyloid protein precursor. Proc. Natl. Acad. Sci. USA, 90, 12045-12049.
21. Li, J. and Le, W. (2013) Modeling neurodegenerative diseases in Caenorhabditis elegans. Exp. Neurol., 250, 94-103.
22. Chakraborty, S., Bornhorst, J., Nguyen, T.T. and Aschner, M. (2013) Oxidative stress mechanisms underlying Parkinson's disease-associated neurodegeneration in C. elegans. Int. J. Mol. Sci., 14, 23103-23128.
23. Yao, C., El Khoury, R.,Wang,W., Byrd, T.A., Pehek, E.A., Thacker, C., Zhu, X., Smith, M.A.,Wilson-Delfosse, A.L. and Chen, S. G. (2010) LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiol. Dis., 40, 73-81.
24. Cao, S., Gelwix, C.C., Caldwell, K.A. and Caldwell, G.A. (2005) Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J. Neurosci., 25, 3801-3812.
25. Lakso, M., Vartiainen, S., Moilanen, A.M., Sirvio, J., Thomas, J. H., Nass, R., Blakely, R.D. and Wong, G. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem., 86, 165-172.
26. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M. and Goedert, M. (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA, 95, 6469-6473.
27. Taymans, J.M. and Cookson, M.R. (2010) Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alphasynuclein, and tau. Bioessays, 32, 227-235.
28. Sawin, E.R., Ranganathan, R. and Horvitz, H.R. (2000) C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron, 26, 619-631.
29. Berkowitz, L.A., Hamamichi, S., Knight, A.L., Harrington, A.J., Caldwell, G.A. and Caldwell, K.A. (2008) Application of a C. elegans dopamine neuron degeneration assay for the validation of potential Parkinson's disease genes. J. Vis. Exp., pii: 835, doi:10.3791/835.
30. Gallogly, M.M., Starke, D.W. and Mieyal, J.J. (2009) Mechanistic and kinetic details of catalysis of thiol-disulfide exchange by glutaredoxins and potential mechanisms of regulation. Antioxid. Redox Signal., 11, 1059-1081.
31. Bisaglia, M., Greggio, E., Beltramini, M. and Bubacco, L. (2013) Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies. FASEB J., 27, 2101-2110.
32. Liu, Z., Yu, Y., Li, X., Ross, C.A. and Smith,W.W. (2011) Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacol. Res., 63, 439-444.
33. Nakabeppu, Y., Tsuchimoto, D., Yamaguchi, H. and Sakumi, K. (2007) Oxidative damage in nucleic acids and Parkinson's disease. J. Neurosci. Res., 85, 919-934.
34. Perry, T.L., Godin, D.V. and Hansen, S. (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett., 33, 305-310.
35. Lopert, P., Day, B.J. and Patel, M. (2012) Thioredoxin reductase deficiency potentiates oxidative stress, mitochondrial dysfunction and cell death in dopaminergic cells. PLoS ONE, 7, e50683.
36. Saeed, U., Ray, A., Valli, R.K., Kumar, A.M. and Ravindranath, V. (2010) DJ-1 loss by glutaredoxin but not glutathione depletion triggers Daxx translocation and cell death. Antioxid. Redox Signal., 13, 127-144.
37. Angeles, D.C., Ho, P., Chua, L.L., Wang, C., Yap, Y.W., Ng, C., Zhou, Z.D., Lim, K.L., Wszolek, Z.K., Wang, H.Y. et al. (2014) Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Hum. Mol. Genet., 23, 3157-3165.
38. Bai, J., Nakamura, H., Kwon, Y.W., Tanito, M., Ueda, S., Tanaka, T., Hattori, I., Ban, S., Momoi, T., Kitao, Y. et al. (2007) Does thioredoxin-1 prevent mitochondria- and endoplasmic reticulum- mediated neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine? Antioxid. Redox Signal., 9, 603-608.
39. Olanow, C.W. and Jankovic, J. (2005) Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov. Disord., 20(Suppl. 11), S3-10.
40. Lou, H., Jing, X., Wei, X., Shi, H., Ren, D. and Zhang, X. (2014) Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway. Neuropharmacology, 79, 380-388.
41. Navarro-Yepes, J., Zavala-Flores, L., Anandhan, A., Wang, F., Skotak, M., Chandra, N., Li, M., Pappa, A., Martinez-Fong, D., Del Razo, L.M. et al. (2014) Antioxidant gene therapy against neuronal cell death. Pharmacol. Ther., 142, 206-230.
42. Leung, C.K., Wang, Y., Malany, S., Deonarine, A., Nguyen, K., Vasile, S. and Choe, K.P. (2013) An ultra high-throughput, whole-animal screen for small molecule modulators of a specific genetic pathway in Caenorhabditis elegans. PLoS ONE, 8, e62166.
43. Yao, C., Johnson,W.M., Gao, Y.,Wang,W., Zhang, J., Deak, M., Alessi, D.R., Zhu, X., Mieyal, J.J., Roder, H. et al. (2013) Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum. Mol. Genet., 22, 328-344.
44. Zhu, X., Babar, A., Siedlak, S.L., Yang, Q., Ito, G., Iwatsubo, T., Smith, M.A., Perry, G. and Chen, S.G. (2006) LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol. Neurodegener., 1, 17.
45. Chrestensen, C.A., Eckman, C.B., Starke, D.W. and Mieyal, J.J. (1995) Cloning, expression and characterization of human thioltransferase (glutaredoxin) in E. coli. FEBS Lett., 374, 25-28.